nogapendekin alfa inbakicept

**Nogapendekin alfa inbakicept** is a recombinant interleukin-15 receptor agonist complex developed by ImmunityBio and commercialized in the United States as **Anktiva**. The complex comprises a modified human IL-15N72D superagonist associated with a dimeric human IL-15 receptor alpha sushi-domain/human IgG1 Fc fusion protein. It promotes proliferation and activation of natural killer cells and CD8-positive effector and memory T cells, supporting innate and adaptive antitumor immunity without intended expansion of regulatory T cells. In April 2024, the FDA approved intravesical Anktiva with Bacillus Calmette-Guérin for adults with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle-invasive-bladder-cancer))

Brand names

Anktiva

Other names

NAInogapendekin alfa inbakicept-pmln